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Specific co-chaperone adaptors facilitate the recruitment of client proteins to the
Hsp90 system. Tah1 binds the C-terminal conserved MEEVD motif of Hsp90,
thus linking an eclectic set of client proteins to the R2TP complex for their
assembly and regulation by Hsp90. Rather than the normal complement of
seven -helices seen in other tetratricopeptide repeat (TPR) domains, Tah1
unusually consists of the first five only. Consequently, the methionine of the
MEEVD peptide remains exposed to solvent when bound by Tah1. In solution
Tah1 appears to be predominantly monomeric, and recent structures have failed
to explain how Tah1 appears to prevent the formation of mixed TPR domain-
containing complexes such as Cpr6–(Hsp90)2–Tah1. To understand this further,
the crystal structure of Tah1 in complex with the MEEVD peptide of Hsp90 was
determined, which shows a helix swap involving the fifth -helix between two
adjacently bound Tah1 molecules. Dimerization of Tah1 restores the normal
binding environment of the bound Hsp90 methionine residue by reconstituting a
TPR binding site similar to that in seven-helix-containing TPR domain proteins.
Dimerization also explains how other monomeric TPR-domain proteins are
excluded from forming inappropriate mixed co-chaperone complexes.
1. Introduction
The R2TP complex is responsible for the cellular stabilization
and assembly of a specific set of proteins and macromolecular
complexes (Te et al., 2007; Zhao et al., 2005), including RNA
polymerase II (Boulon et al., 2010; Forget et al., 2010), small
nucleolar ribonucleoproteins (snoRNPs; Gonzales et al., 2005;
Kakihara & Houry, 2012; Kurokawa et al., 2008; Samarsky
et al., 1998) and phosphatidylinositol-3-kinase-like kinases
(PIKKs) such as mTOR and SMG1 (Horˇejsˇı´ et al., 2010; Takai
et al., 2010). The R2TP complex consists of the AAA+ATPase
Rvb1 and Rvb2 heterododecamer complex (RUVBL1 and
RUVBL2 in humans), a tetratricopeptide (TPR)-containing
protein (Tah1, or RPAP3 in humans and Spag/Spaghetti in
Drosophila) and Pih1 (also known as NOP17) (Kakihara &
Houry, 2012; Te et al., 2007). The recruitment of Hsp90 by
the R2TP complex is essential for its biological role (Pal et al.,
2014; Boulon et al., 2010; Izumi et al., 2012; Takai et al., 2010).
In yeast, Tah1 acts as the direct link between the R2TP
complex and Hsp90 by binding the C-terminal conserved
MEEVD peptide motif of the chaperone and the C-terminal
region of Pih1 (Eckert et al., 2010). In metazoa, the interaction
of Pih1 with Hsp90 is mediated by Spag/RPAP3 (Itsuki et al.,
2008), a larger protein containing two N-terminal TPR
domains as well as additional domains of unknown function.
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Recently, NMR and crystal structures (Pal et al., 2014; Back
et al., 2013; Jime´nez et al., 2012) revealed that Tah1 consists of
five -helices, rather than the typical seven -helices observed
in other TPR domains that bind the Hsp90 MEEVD peptide.
A virtually identical twisted Hsp90 peptide conformation and
set of interactions is observed in these structures and those of
CHIP and AIP (Morgan et al., 2012; Zhang et al., 2005; Pal et
al., 2014; Back et al., 2013), even though Tah1 lacks the two
C-terminal -helices (6 and 7). Consequently, the hydrophobic
pocket that is normally formed by amino-acid residues from
-helices 5 and 7, as seen in AIP and CHIP, is incomplete and
the methionine of the MEEVD peptide remains exposed to
the solvent. Curiously, the TPR1 and TPR2 domains of Spag/
RPAP3 appear to possess the normal complement of -helices
such that the methionine-accepting hydrophobic pocket is
intact (Pal et al., 2014). This suggests that the full molecular
details by which the MEEVD peptide of Hsp90 binds the yeast
Tah1 protein have still not been fully elucidated.
In solution, Tah1 appears to be predominantly monomeric
and binds Hsp90 as a 1:1 stoichiometric (two Tah1 monomers:
one Hsp90 dimer) complex (Pal et al., 2014). This complex
excludes interaction with Cpr6 and thus prevents the forma-
tion of a Cpr6–(Hsp90)2–Tah1 mixed co-chaperone complex
(Pal et al., 2014). However, the mechanism by which this
occurs remains elusive. The exclusion of co-chaperones that
are not normally part of a specific Hsp90 client–protein
complex is fundamentally essential for the proper activation of
client proteins. Homodimerization of a specific TPR-domain
protein following Hsp90 binding is a possible mechanism by
which other monomeric TPR-domain proteins would be
excluded from simultaneously binding. Homodimerization
would thus allow both MEEVD sites of Hsp90 to be simul-
taneously occupied. The fact that Tah1 is weakly dimeric in
solution (Pal et al., 2014) raises this as a distinct possibility,
although to date direct structural dimerization of Tah1 has not
been observed (Back et al., 2013; Jime´nez et al., 2012; Pal et al.,
2014). Theoretically, dimerization of Tah1 could also provide
the extra shielding from solvent of the methionine of the
bound MEEVD peptide of Hsp90.
To address these questions, we have obtained a new crystal
form of Tah1 in complex with the EDASRMEEVD peptide of
Hsp90 that reveals a swap between -helix 5 of two adjacently
Hsp90-bound Tah1 molecules. The dimerization of Tah1
reconstitutes the typical MEEVD binding mode observed with
seven-helix-containing TPR domains such as AIP and CHIP
(Morgan et al., 2012; Zhang et al., 2005) and explains how
other monomeric TPR proteins are excluded from binding
simultaneously.
2. Methods
2.1. Protein purification
For selenomethionine (SeMet) labelling, Escherichia coli
Rosetta DE3 cells containing the appropriate expression
vector were grown in minimal medium supplemented with
SeMet. Synthetic full-length yeast Tah1 was expressed from
pRSET-A. Tah1 was purified by Talon affinity chromato-
graphy (Clontech, Oxford, England) equilibrated in 20 mM
Tris pH 7.5 containing 100 mM NaCl and eluted with the
same buffer but containing 500 mM imidazole at pH 7.0. The
protein was then concentrated using Vivaspin concentrators
(5000 Da molecular-weight cutoff) and subjected to Superdex
75 HR gel-filtration chromatography equilibrated in 20 mM
Tris pH 7.5 containing 500 mM NaCl, 0.5 mM TCEP. Pure
Tah1 was dialyzed in 10 mM HEPES pH 7.5, 140 mM NaCl,
0.5 mM TCEP and then concentrated to 10 mg ml1 in the
presence of 5 mM Hsp90 peptide (EDASRMEEVD) and
stored frozen at 20C. Purification of AIP was as previously
described (Morgan et al., 2012).
2.2. Crystallography
The Tah1–EDASRMEEVD complex was crystallized using
the sitting-drop method with protein at 10 mg ml1 in 140 mM
NaCl, 10 mM Na HEPES pH 7.8, 0.5 mM TCEP against wells
containing 100 mMMES pH 6.0, 200 mM ammonium chloride,
20% PEG 6000 at 4C. Crystals were harvested by successive
transfer into crystallization buffer with increasing ethylene
glycol content to 30% and then flash-cooled in liquid nitrogen.
Diffraction data were collected from crystals cooled to 100 K
on an in-house Rigaku MicroMax-007 HF generator at the Cu
wavelength. Data were processed with iMosflm (Battye et al.,
2011) and the asymmetric unit contents were estimated using
the Matthews coefficient (CCP4 suite; Krissinel et al., 2004).
The Tah1–EDASRMEEVD structure was solved using Phaser
(CCP4) with the model of Tah1 from the EDASRMEEVD–
Tah1–Pih1p187–344 complex (Pal et al., 2014). The structure of
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Table 1
Crystallographic statistics for Tah1–SRMEEVD.
Values in parentheses are for the highest resolution shell.
Data-collection statistics
Unit-cell parameters
a (A˚) 62.79
b (A˚) 62.79
c (A˚) 57.90
, ,  () 90, 90, 90
Space group P43212
Wavelength (A˚) 1.5419
Resolution limits (A˚) 13.8–2.00 (2.05–2.00)
No. of observations 8230 (590)
Completeness (%) 99.7 (100.0)
Multiplicity 10.3 (10.0)
Rmerge 0.098 (0.481)
Rp.i.m.(I) 0.060 (0.223)
Mean I/(I) 7.9 (3.0)
Refinement
Resolution range (A˚) 13.8–2.00
Rcryst 0.1628
Rfree 0.2102
No. of protein atoms 806
No. of ligand atoms 1
No. of solvent atoms 98
Mean B factor (A˚2)
Protein 20.8
Ligands 15.3
Solvent 34.0
R.m.s.d., bond lengths (A˚) 0.019
R.m.s.d., bond angles () 1.791
Tah1–EDASRMEEVD was refined with REFMAC 5.7
(Murshudov et al., 2011) and manual rebuilding was
performed in Coot (Emsley & Cowtan, 2004). Only the
SRMEEVD residues of the Hsp90 peptide were visible. The
structure was deposited in the PDB (PDB entry 4cgq) and was
displayed using PyMOL (Schro¨dinger, USA).
2.3. Pulldowns and gel filtration
Increasing concentrations of AIP172–315 or full-length AIP
and 70 mM Flag-Tah1 and Hsp90600–709 were incubated in
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Figure 1
Structures of Tah1 and AIP. (a) Secondary-structure cartoon of the Tah1
TPR-domain dimer (cyan and green). The fifth helix of one TPR domain
intercalates between the fourth and fifth helices of the other, generating
an effective six-helix two-TPR-domain structure. The bound Hsp90
C-terminal peptides are shown as magenta sticks. Helices are numbered
1–5 and M represents the conserved methionine residue of the
EDASRMEEVD peptide (only SRMEEVD was visible), now bound in
a hydrophobic pocket formed by amino-acid residues Val74, Ser78, Lys79,
Gln81, Tyr82 and Arg83 of Tah1. (b) Secondary-structure cartoon of the
monomeric TPR domain of Tah1 (yellow) with bound SRMEEVD
peptide derived from the C-terminus of Hsp90 (green sticks). Helices are
numbered 1–5 and M represents the conserved methionine residue of the
EDASRMEEVD peptide (only SRMEEVD was visible). (c) Secondary-
structure cartoon of the TPR domain of AIP (yellow) bound to the
SRMEEVD peptide derived from the C-terminus of Hsp90 (green
sticks). Helices are numbered 1–5 and M represents the conserved
methionine residue of the EDASRMEEVD peptide (only SRMEEVD
was visible).
Figure 2
Gel-filtration analysis of Tah1. (a) Calibration of the Superdex 75 HR gel-
filtration column with protein standards. BSA, bovine serum albumin;
OA, ovalbumin; CA, carbonic anhydrase; RN, ribonuclease A; AP,
aprotinin. The molecular mass of each standard protein is indicated in
kDa. (b) Gel-filtration profile of Tah1. Monomeric Tah1 clearly elutes
with a molecular weight of 14.1 kDa, with no indication of a shoulder or
a second peak that might represent the presence of dimeric Tah1. This
suggests that Tah1 is mainly monomeric in solution. The arrow indicates
the expected elution volume of dimeric Tah1. mAU, milliabsorbance
units.
20 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 0.5%
IGEPAL, 2 mM EDTA. Subsequently, 30 ml anti-Flag M2
magnetic beads (Sigma–Aldrich) were added. The beads were
then washed and the eluate was subjected to SDS–PAGE.
Superdex 75 gel-filtration chromatography was used to
determine the presence of dimeric Tah1. The column was
equilibrated with 20 mM Tris–HCl, 140 mM NaCl pH 7.5,
0.5 mM TCEP and calibrated using standard molecular-weight
markers (bovine serum albumin, 67 kDa;
ovalbumin, 44 kDa; carbonic anhydrase,
29 kDa; ribonuclease, 13.7 kDa; aprotinin,
6.5 kDa).
3. Results
3.1. Structure of the Tah1–Hsp90 MEEVD
complex
The structure of a complex between the
TPR domain of Tah1 and the Hsp90 peptide
EDASRMEEVD (residues 1–7 of which,
S1RMEEVD7, are the only residues visible
in the structure) was solved by single-
wavelength anomalous diffraction (see x2)
and refined to 2 A˚ resolution (Table 1).
97.4% (299 out of 307) of all residues were
in favoured (98%) regions and 100.0% (307
out of 307) of all residues were in allowed
(>99.8%) regions (Supplementary Fig. S1).
The structure reveals that two Tah1 mole-
cules form an intimate dimer by symmetrical
exchange of their C-terminal -helices
(Fig. 1a), in contrast to the structures
previously observed for Tah1 (Pal et al.,
2014; Back et al., 2013; Jime´nez et al., 2012;
Fig. 1b) and other TPR-domain proteins
such as AIP (Fig. 1c), and supports the
observation that Tah1 appears to be a weak
dimer in solution (Pal et al., 2014). Weak
dimer formation by Tah1 was confirmed
by gel-filtration chromatography, which
showed that Tah1 was predominantly
monomeric in solution with no significant
dimer peak (Fig. 2).
The dimeric Tah1 structure reveals that
the -helix swap seen between two mole-
cules of Tah1 reconstructs the hydrophobic
binding pocket that accepts the conserved
methionine of the SRMEEVD peptide
(compare Figs. 3a and 3b). The Hsp90
peptide essentially adopts the same confor-
mation as previously seen in Tah1 (mono-
meric) and AIP structures, including the
important carboxylate-clamp interaction
(Fig. 4). Consequently, the interactions
made in previous Tah1 structures are
retained in the dimer complex (compare
Figs. 3a and 3b; Pal et al., 2014). However, some additional
interactions are seen in the dimeric structure. Interactions
between the Hsp90 peptide and the Arg77, Lys79, Gln81,
Tyr82 and Arg83 residues of Tah1 are provided by the
swapped C-terminal -helix from the other monomer
(Fig. 3b). Significantly, Gln81 not only makes a set of new
interactions with the MEEVD peptide but also completes the
hydrophobic pocket into which the methionine of the Hsp90
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Figure 3
Stereo PyMOL images of the interactions of the Hsp90 peptide with monomeric and dimeric
Tah1. (a) Detail of interactions of the monomeric Tah1 TPR domain and the Hsp90 C-terminal
SRMEEVD peptide. The Hsp90 peptide binds with a compacted conformation stabilized by
interaction of the side chain of Glu4 with the side chains of Lys50 and Tyr82 of Tah1. The
backbone carbonyl of Glu5 is stabilized by interactions with the side chains of Lys79 and Arg83
of Tah1. The peptide carbonyl of Met3 is also stabilized by interaction with the side chain of
Arg83. The -carboxyl and carboxylate side chain of Asp7 is bound by a ‘carboxylate clamp’
formed by residues Lys8, Asn12, Asn43 and Lys79 of Tah1. The side chain of Met3 in the Hsp90
peptide packs against Tyr82, but is far more exposed than seen in other Hsp90–TPR domain
complexes. M represents the conserved methionine residue of the EDASRMEEVD peptide
(only SRMEEVD was visible). (b) Detail of the interactions of the Hsp90 C-terminal
SRMEEVD peptide with the helix-swapped Tah1 TPR domain dimer. Essentially the same set
of interactions occurs as in the monomeric TPR (Fig. 3a), but with residues from both TPR
domains in the dimer. Additional dimer-specific polar interactions occur between Glu4 of the
Hsp90 peptide and Gln81 of Tah1 and between the peptide backbones of Glu72 and Val74 of
Tah1 and the N-terminal end of the peptide, while Met3 becomes buried in a hydrophobic
pocket formed by Tah1 residues Val74, Ser78, Lys79, Gln81, Tyr82 and Arg83. M represents the
conserved methionine residue of the EDASRMEEVD peptide (only SRMEEVD was visible).
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peptide binds. In Tah1 this position shows amino-acid residue
conservation even though these residues are exposed to
solvent in the monomeric structures (Fig. 5).
The formation of the swapped helix dimer sees the first turn
of the fifth -helix unravel to form an extended segment of
polypeptide chain that allows swapping of the rest of the helix
into the TPR structure of the other monomer. The residues
forming this extended segment also provide additional
interactions with the Hsp90 peptide, including main-chain
hydrogen bonds between the Glu72 and Val74 residues of
Tah1 and the first residue (Ser1) of the bound peptide. The
side chain of Val74 of Tah1 also packs against the side chain
of Met3 in the Hsp90 peptide, thus fully enclosing it in a
hydrophobic pocket (Fig. 3b). The helix exchange observed
in the dimerized five-helix TPR structure of Tah1 therefore
restores the hydrophobic burial of the methionine side chain
of the Hsp90 peptide, similar to that observed in seven-helix
TPR domains.
Figure 4
Hsp90 peptide conformations. (a) Cartoon superimposition of the Tah1–Pih1 (yellow) structure and the Tah1 dimeric structure (green and cyan) showing
that the bound Hsp90 peptides [shown as tubes in magenta for the dimer structure and yellow for the Tah1 (monomer)–Pih structure] are bound in
essentially the same conformation. (b) Superimposition of the Tah1-bound (cyan) and the AIP-bound (green) EDASRMEEVD Hsp90 peptides (only
SRMEEVD is visible) showing that they bind in essentially the same conformation. (c) Cartoon stick model showing the carboxylate-clamp interactions
between the Hsp90 peptide EDASRMEEVD (green; only SRMEEVD is visible) and Tah1 amino-acid residues (yellow).
3.2. The start of a-helix 5 of Tah1 is metastable
Fundamental to the formation of the Tah1 helix-swap dimer
is the unravelling of the start of helix 5. Thus, we compared a
number of monomeric Tah1 structures to understand whether
this region was structurally variable (Pal et al., 2014; Back et
al., 2013). Analysis showed that the MEEVD peptide of Hsp90
binds in essentially the same conformation and that the
methionine is exposed to solvent in all cases (Fig. 6a).
However, the most divergent part of the structure, apart from
the unstructured C-terminal extension of Tah1, was the start
of -helix 5 and the loop leading to it (Fig. 6a). This analysis
suggests that this region of Tah1 is probably metastable and
might help to initiate the movement of -helix 5 towards the
formation of the helix-swapped state.
We next investigated whether the crystallization contacts
between the loop connecting helices 4 and 5 of Tah1 and the
other Tah1 molecules in the crystal lattice might have induced
the helix-swapped conformation. The section of the fifth helix
that unwinds (Thr70–Tyr74) is the same section as is involved
in crystallization contacts. Specifically, the main-chain amide
group of Ser69 makes a hydrogen-bond interaction with the
carbonyl group of Glu22 of a neighbouring molecule. This
appears to be the only stable hydrogen-bond interaction.
The side-chain hydroxyl group of Ser69 and the main-chain
carbonyl group of Thr70 are also hydrogen-bonded, via a
water-mediated interaction, to one of the guanidinium N
atoms of Arg21 of the adjacent molecule. However, Arg21 and
Ser69 are both seen to adopt alternate conformations,
indicating that these are not very stable
interactions (Fig. 6b). It therefore
appears that the interface between the
loop connecting helices 4 and 5 and the
neighbouring Tah1 molecule is rather
weak. In contrast, the interactions
formed between the loop and the bound
MEEVD peptide are significantly more
extensive and stable and include inter-
actions with Ala71, Glu72 and Val74
(Fig. 3b).
3.3. Tah1 binding excludes the binding
of monomeric AIP
Previously, we had shown that Tah1
binding to Hsp90 could prevent the
simultaneous binding of Cpr6 (Pal et al.,
2014). To further validate this, we also
tested the ability of AIP (aryl hydro-
carbon receptor-interacting protein),
a monomeric TPR domain-containing
protein, to form a mixed co-chaperone
complex with Tah1. Tah1 binds with a
slightly higher affinity than that of AIP
(Kd = 5.9 and 13.3 mM, respectively), so
we used a 5–10 molar excess of AIP
(both AIP172–315 and full-length AIP;
Morgan et al., 2012). We found that AIP
did not pull down with any Tah1 by
forming a mixed Tah1–Hsp90–AIP
complex (Fig. 7). Thus, we conclude that
dimerization of Tah1 following binding
to Hsp90 appears to prevent the binding
of AIP and Cpr6, as previously observed
(Pal et al., 2014).
3.4. Dimerization of Tah1 reconstitutes
a more complete TPR domain that is
compatible with the binding of Pih1
When the Tah1 TPR domain from
the structure of the Pih1–Tah1–Hsp90
peptide complex is superimposed on
one monomer of the helix-swapped
Tah1 dimer, the endogenous C-terminal
helix from the former almost precisely
overlays the exogenous C-terminal helix
from the other Tah1 monomer in the
dimeric structure (Fig. 8). This recon-
stitutes a more complete TPR domain,
which although missing helix 6 (Fig. 8)
maintains all of the essential contacts
(compare Figs. 3a and 3b) required to
satisfy the binding of the MEEVD
peptide of Hsp90 (Pal et al., 2014;
Morgan et al., 2012; Zhang et al., 2005).
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Figure 5
Conservation of amino-acid residues of Tah1. (a) Sequence alignment showing conserved residues
in Tah1 sequences. Position 81 is indicated. TETPH, Tetrapisispora phaffii; KLUMA,
Kluyveromyces marxianus; NAUCC, Naumovozyma castellii; SACCE, Saccharomyces cerevisiae;
SACAR, Saccharomyces arboricola. Asterisks and dots below the alignment signify the degree of
conservation. (b) Monomeric Tah1 showing the solvent-exposed position of Gln81. M represents
the methionine residue of the MEEVD peptide. (c) Dimeric Tah1 showing the interactions made by
the Gln81 residues of Tah1. M represents the methionine residue of the MEEVD peptide.
Superimposition of Tah1 from the Tah1–Pih1 CS domain
complex onto the dimeric Tah1 structure reveals no steric
clash involving the Pih1 CS domain that might preclude each
Tah1 bound to the C-terminus of Hsp90 from recruiting a Pih1
molecule (Fig. 9). This is consistent with results showing that
Hsp90 binds Tah1 and preassembled Tah1–Pih1 complex not
only with a 1:1 stoichiometry but also with similar affinity
(Kd = 5.9  0.3 and 4  0.7 mM, respectively; Pal et al., 2014).
The similar affinity and binding stoichiometry are consistent
with the formation of an (Hsp90)2–(Tah1)2–(Pih1)2 complex in
which the Tah1 molecules are dimerized.
4. Discussion
The Hsp90 molecular-chaperone system is responsible for the
assembly, stabilization and activation of a variety of proteins
and complexes from protein kinases, including phosphatidyl-
inositol 3-kinase-related kinases (PIKKs), to steroid hormone
receptors, NLR innate immunity receptors and both viral
and cellular DNA and RNA polymerases (Pearl et al., 2008;
Prodromou, 2012). Recruitment of client proteins to the
Hsp90 system is mediated by specific co-chaperones that act as
adaptors linking the client protein to Hsp90. For example, the
Cdc37 co-chaperone recruits conventional protein kinases to
Hsp90 (Vaughan et al., 2006). During loading, the ATPase-
coupled conformational cycle of the chaperone is halted as
well as the kinase activity of the client protein (Siligardi et al.,
2002; Roe et al., 2004; Polier et al., 2013). Similarly, the dimeric
TPR domain-containing protein HOP (Sti1 in yeast) delivers
the steroid hormone–Hsp70 complex to Hsp90 while simul-
taneously silencing the ATPase activity of Hsp90. In contrast,
PIKKs, RNA polymerase II and the snoRNPs and chromatin-
remodelling complexes are recruited to Hsp90 by a far more
complicated system involving a chain of protein interactions
mediated by Tah1 (or Spag/RPAP3), which couples the R2TP
complex to Hsp90 (Kakihara & Houry, 2012). In particular,
the recruitment of PIKKs involves a far more protracted
and potentially convoluted link between client protein and
chaperone that utilizes the TTT complex (TEL2, TTI1 and
TTI2; Pal et al., 2014).
The interaction of Tah1 with Hsp90 is therefore crucial in
recruiting Hsp90 into complex with R2TP-dependent client
proteins. Here, we show that Tah1 undergoes a previously
unobserved molecular rearrangement that results in a swap
between the C-terminal -helices of two adjacent Tah1
molecules. The intimate homodimer that is created reforms
the hydrophobic binding pocket responsible for binding the
conserved methionine residue of the MEEVD peptide of
Hsp90. Ultimately, the helix swap allows the fifth helix of Tah1
to be involved in roles not only observed for helix 5 but also
for helix 7 in conventional TPR domains such as AIP and
CHIP (Morgan et al., 2012; Zhang et al., 2005). Exchange of
secondary structures or even whole domains as part of dimer
formation is a well known phenomenon (Liu & Eisenberg,
2002; Nagradova, 2002) and indeed plays a role in the
N-terminal domain association that occurs as part of the
ATPase-coupled conformational cycle of Hsp90 itself (Ali et
al., 2006).
Compelling evidence for the dimerization of Tah1 is
provided by several observations. Significantly, there is strong
amino-acid residue conservation at position 81 (Gln81 in
S. cerevisiae Tah1) on the solvent-exposed surface of the fifth
helix in the monomeric Tah1. The residue at this position
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Figure 6
Superimposition of monomeric Tah1 structures. (a) Tah1 monomeric
structures are superimposed. Magenta represents Tah1 from the structure
of the Tah1–Pih complex (PDB entry 4cgu; Pal et al., 2014), while green
and cyan are solution structures (PDB entries 2lsu and 2lsv, respectively;
Back et al., 2013). Helices 5 and 4 are labelled. The tubes in magenta and
cyan represent the bound Hsp90 peptide. (b) Crystallographic interface
between the loop connecting -helices 4 and 5 and an adjacent Tah1
monomer. Yellow and green represent the two halves of a Tah1 dimer in
contact with an adjacent Tah1 molecule (shown in cyan). Hydrogen bonds
are shown as dotted blue lines, while water molecules are shown as red
spheres.
varies from glutamine to asparagine or lysine, all of which
could potentially interact with the bound Hsp90 peptide and
simultaneously provide the shielding needed to complete the
hydrophobic pocket. The fact that Gln81 is centrally impor-
tant in the interaction with the MEEVD peptide while not
disrupting the peptide-binding conformation, and simulta-
neously completes the hydrophobic binding pocket, is strong
evidence that biologically Tah1 functions by dimerization.
Ultimately, a prerequisite to the formation of a dimerized state
is the unwinding of the first part of helix 5 of Tah1, and on
comparing a variety of monomeric Tah1 structures this region
shows significant structural variability and appears to be
rather metastable. The metastable nature at the beginning of
the fifth -helix of Tah1 appears to be an inherent property of
this domain and is probably essential for initiating the helix
swap. It also appears from our analysis that it is very unlikely
that the helix-swapped conformation was induced by a
crystallographic contact. The loop connecting helices 4 and 5
of Tah1 makes a very poor crystallization interface and the
stability of this interface appears to be very much weaker than
the apparent biologically relevant interactions formed by helix
5 in the swapped position. Taken together, these observations
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Figure 7
Dimerization of Tah1 prevents AIP binding. SDS–PAGE gels showing that Tah1 prevents the formation of a Tah1–cHsp90–AIP mixed complex. (a)
Control pulldowns in the presence of AIP172–315 (left panel) or full-length AIP, Flag-Tah1 or cHsp90 alone (right panel). (b) Pulldowns with Flag-Tah1 in
the presence of cHsp90 and increasing amounts of AIP172–315 (left panel) or full-length AIP (right panel). A fivefold to tenfold excess of either AIP172–315
or full-length AIP does not pull down with the Flag-Tah1–cHsp90 complex, indicating that a three-way complex with AIP does not form. Arrows indicate
the positions of the various proteins used.
provide compelling evidence that dimerization of Tah1 forms
the biologically active state that is able to prevent mixed TPR
complexes from forming.
Other TPR domain-binding proteins have also been seen to
form dimers, but the precise mechanism varies. For example,
the C-terminal TPR domains of Sti1 have long been known to
be responsible, at least in part, for the dimerization of this
protein (Prodromou et al., 1999). However, molecular details
of this dimerization have not been forthcoming. Furthermore,
the TPR domain of Sgt1 (suppressor of G2 allele SKP1, not
to be confused with Sgt2 and SgtA) has also been shown to
homodimerize, although structural detail of this is also lacking
(Nyarko et al., 2007). In contrast, Sgt2 and SgtA (small
glutamine-rich TPR-containing protein) have an N-terminal
dimerization domain (Tung et al., 2013; Liou & Wang, 2005;
Chartron et al., 2012; Tobaben et al., 2003), as does the
orthologue from Caenorhabditis elegans (Worrall et al., 2008),
for which structural details of the dimerization have recently
been reported (Chartron et al., 2012). These differ from those
of Tah1 and suggest that many different mechanisms of
dimerization may be employed by TPR domain-containing
proteins.
We also considered testing the dimerization interface by
site-directed mutagenesis as a means to test the observed
dimeric state of Tah1 when bound to Hsp90. However,
because the swapped helices are placed in exactly the same
positions as if they had not been swapped, theoretically
dimerization of Tah1 can still occur without a helix swap
occurring. Essentially the same dimeric state is formed except
for some additional interactions with the Hsp90 peptide that
result from the uncoiling of the fifth helix of Tah1 that allows
helix swapping. However, the additional interactions seen in
the Tah1 swapped dimer might lead to increased stability and
thus a more stable dimer than one that had not undergone
helix swapping. The fact that both dimeric states are essen-
tially the same prevents the helix-swap model from being
directly tested by most simple biochemical techniques,
including mutagenesis. However, the arrangement of the
helix-swapped conformation is fundamentally more stable
than one in which the helices have not undergone exchange.
Swapping of the helices requires that two interfaces, one
between the fifth helices and the other between helices 4 and 5
of the neighbouring molecule, are disrupted in order for the
dimer to separate into monomers. However, in a straightfor-
ward dimer situation in which the helices have not swapped,
only the interface between the fifth helices needs to be
disrupted. The extra stability offered in a helix-swapped dimer
argues, from a thermodynamic point of view, in favour of the
helix-swapped structure being the relevant biological dimer
and possibly explains why this conformation was observed in
the crystals.
Ultimately, the dimerization of Tah1, whether by helix
swapping or not, does explain how a predominantly mono-
meric TPR protein (in solution) prevents mixed TPR–Hsp90–
Tah1 complexes, such as Tah1–(Hsp90)2–(Cpr6 or AIP) from
forming (Pal et al., 2014). Furthermore, it explains how the
normal hydrophobic pocket that accepts Met3 of the Hsp90
peptide is reformed in line with the human homologue
Spag/RPAP3. Whether homodimerization of TPR domain-
containing proteins is a universal mechanism that controls and
prevents the formation of mixed TPR domain-containing
protein complexes with Hsp90 remains to be seen.
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Figure 9
Dimerization of Tah1 permits Pih1 binding. Superimposition of
secondary-structure cartoons of dimeric Tah1 (green and cyan) and
Pih1 (yellow) bound to Tah1, showing that dimerization of Tah1 does not
result in steric hindrance to the binding of Pih1. SRMEEVD represents
the visible peptide of Hsp90 that was bound (magenta tubes).
Figure 8
Dimerization of Tah1 reconstitutes a six-helix TPR domain. Super-
imposition of secondary-structure cartoons of dimeric Tah1 (green and
cyan), monomeric Tah1 (yellow) and AIP (salmon). The helices of AIP
are numbered 1–7. The swapped helices in the Tah1 dimer reconstruct the
approximate position of helices 5 and 7 in the AIP structure.
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